<DOC>
	<DOCNO>NCT01724606</DOCNO>
	<brief_summary>Sorafenib new type anti-cancer drug . It belong new class medication know tyrosine kinase inhibitor . Sorafenib think work cancer many way . It help decrease blood supply tumor . It also block protein help tumor cell grow . '' Sorafenib approve Food Drug administration ( FDA ) treatment cancer like liver kidney cancer . Sorafenib also study treatment breast cancer spread specifically approve treatment breast cancer . It study single agent also combination anti-cancer therapy breast cancer . In laboratory model patient cancer , sorafenib study tumor brain . In study , sorafenib give together whole brain radiation therapy ( WBRT ) . Overall research study design answer 2 main question : 1 . What dose sorafenib use together WBRT ? 2 . What side effect sorafenib WBRT give together ?</brief_summary>
	<brief_title>Whole Brain Radiotherapy ( WBRT ) With Sorafenib Breast Cancer Brain Metastases ( BCBM )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologicallyconfirmed metastatic adenocarcinoma breast ( Confirmation do MSKCC ) Age ≥18 year . Radiologic evidence new and/or progressive brain metastasis ( ≥10 mm long dimension ) MR image Brain Life expectancy &gt; 12 week . Karnofsky Performance Status ( KPS ) ≥70 % If patient corticosteroid , he/she must nonescalating corticosteroid dose ( exceed 16 mg daily Dexamethasone oral ) ≥ 5 day . No limit prior therapy last anticancer treatment ≥ 2 week initiation protocol base therapy provide toxicity ( alopecia ) resolve ≤Grade 1 baseline . Planned WBRT base number ( ≥ 3 lesion ) and/or size ( ≥ 1 cm ) BMs ( SRS ) addition WBRT also eligible . Patients prior SRS also eligible , provide new , nonirradiated measurable brain lesion . No limit prior therapy last anticancer treatment ≥2 week initiation WBRT . Please note : washout period require trastuzumab pertuzumab . Prior hormonal therapy locally advance metastatic disease allow must discontinue prior enrollment . No washout period require . Continuation trastuzumab pertuzumab allow patient already trastuzumab pertuzumab therapy . Adequate bone marrow , liver , renal function assess follow : Granulocyte count ≥ 1,000/μL , platelet count ≥ 100,000/μL , hemoglobin ≥ 10 g/dL ( hematologic parameter must assess least 14 day prior transfusion , ) Serum bilirubin ≤ 1.5 mg/dL ; AST , ALT , alkaline phosphatase ≤ 2.5 × ULN except : Patients hepatic metastasis : ALT AST ≤ 5 × ULN ; patient hepatic and/or bone metastasis : alkaline phosphatase ≤ 5 × ULN patient Gilbert 's disease : serum bilirubin &lt; 5 mg/dL Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min base 24hour urine collection Women childbearing potential must negative serum pregnancy test perform within 7 day prior enrollment must agree use adequate contraception prior enrollment duration study participation . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 30 day last dose study drug . Patients must able swallow retain oral medication . Leptomeningeal metastasis , hemorrhagic metastasis , presence midline shift Please note : leptomeningeal metastasis may allow limited cranial metastasis ( MRI spine complete , within 4 week enrollment , show leptomeningeal metastasis present ) metastasis present brain . ' Contraindications sorafenib Prior treatment agent target vascular endothelial growth factor ( VEGF ) VEGF receptor ( VEGFR ) ( licensed investigational include sorafenib ) , except bevacizumab . Craniotomy major surgery , open biopsy , significant traumatic injury within 4 week enrollment . Serious , nonhealing wound , ulcer , bone fracture . Uncontrolled seizure Use cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine , phenobarbital ) allow . Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) ( See Appendix B , Unstable angina ( anginal symptom rest ) , newonset angina ( begin within last 3 month ) , myocardial infarction within 6 month prior enrollment , Cardiac ventricular arrhythmia require antiarrhythmic therapy . Congenital long QT syndrome take drug know prolong QT interval ( See Appendix D http : //www . Azcert.org ) Subjects take drug know risk cause torsades de pointes . Grade 3 hypertension ( SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg despite maximal medical therapy ) ≥ Grade 2 Lipase increase ( &gt; 1.5 x ULN ) , Thrombolic , embolic , venous , arterial event cerebrovascular accident include transient ischemic attack within past 6 month . Evidence history bleed diathesis coagulopathy time enrollment . Pulmonary hemorrhage/bleeding event &gt; National Cancer Institute Common Terminology Adverse Events ( NCICTCAE , version 4.0 ) Grade 2 within 4 week enrollment . Any hemorrhage/bleeding event ≥NCICTCAE Grade 3 within 4 week enrollment . Therapeutic anticoagulation VitaminK antagonist ( e.g. , warfarin ) heparins heparinoids . However , prophylactic anticoagulation describe allow : Low dose warfarin ( 1 mg orally , daily ) PTINR ≤ 1.5 x ULN permit . Infrequent bleed elevation PTINR report subject take warfarin sorafenib capecitabine therapy . Therefore , subject take concomitant warfarin monitor regularly change PT , PTINR clinical bleeding episode . Low dose aspirin ( ≤ 100 mg daily ) . Active clinically serious infection &gt; NCICTCAE Grade 2 . Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C ( safety effectiveness sorafenib patient population study ) . Previous concurrent cancer distinct primary site histology breast cancer within 5 year prior enrollment EXCEPT cervical cancer situ , treat basal cell carcinoma , squamous cell carcinoma ( SCC ) , long SCC involve skin head and/or neck , superficial bladder tumor [ Ta Tis ] . Subjects use strong CYP3A4 inducer ( eg , phenytoin , carbamazepine , phenobarbital , St. John 's Wort [ Hypericum perforatum ] , dexamethasone dose great 16 mg daily one day , rifampin [ rifampicin ] , and/or rifabutin ) within 28 day randomization . Concurrent anticancer therapy ( chemotherapy , hormonal therapy , radiation therapy ( specify protocol ) , surgery , immunotherapy , biologic therapy include trastuzumab , lapatinib , bevacizumab , tyrosine kinase inhibitor sorafenib tumor embolization Women pregnant breastfeeding . Use investigational drug within 28 day 5 halflives , whichever longer , precede enrollment . For purpose study , bevacizumab consider investigational therapy . Inability comply protocol /or willing available followup assessment . Any condition investigator 's opinion make patient unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Whole Brain Radiotherapy ( WBRT )</keyword>
	<keyword>Sorafenib ( BAY 43-9006 )</keyword>
	<keyword>12-046</keyword>
</DOC>